CA
CABA
Cabaletta Bio, Inc.
$3.22
+0.62%
$521.8M
No data for this timeframe.
Vol
Market Cap$521.8M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (81%)
Inst. Holders8 funds
Inst. Value$20.2M
Inst. Activity1 buys / 2 sells
Reddit Sentiment75° Bullish
SEC Reports11
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001759138·Prev Close $3.20
Recent Activity
Jun 5, 2026
SEC
Cabaletta Bio presented updated Phase 1/2 clinical data for rese-cel across multiple autoimmune indications at EULAR 202
8-K — Impact 7/10
Jun 3, 2026
other
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
<p align="center"><em>83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would ha
Jun 1, 2026
SEC
Cabaletta Bio's board withdrew Proposal 3 (amendment to the 2019 Stock Option and Incentive Plan) from the June 9, 2026
DEFA14A — Impact 3/10
May 14, 2026
SEC
Cabaletta Bio presented new clinical data at ASGCT 2026 showing that 2 of 4 refractory pemphigus vulgaris patients achie
8-K — Impact 7/10
Mar 2, 2026
Insider
Chang David J. sold 225,000 shares
Chief Medical Officer @ $0.00 ($0.00)
Mar 2, 2026
Insider
Nichtberger Steven sold 674,000 shares
President & CEO @ $0.00 ($0.00)
Mar 2, 2026
Insider
Marda Anup sold 225,000 shares
Chief Financial Officer @ $0.00 ($0.00)
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
1,839,799 shares ($4.0M)
Price Targets
$13.38
+315.4% upside
Strong Buy
Current $3.22
Low $4.00
Median $13.50
High $30.00
8 analysts
$4.00
$30.00
Analyst Ratings
6Strong Buy
7Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2026 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
| May 4, 2026 | Cantor Fitzgerald | REITERATE | Overweight → Overweight |
| Mar 24, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| Mar 24, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.34 ▲ +21.2% | $-0.41 — $-0.26 | 53% YoY | 4 |
| Next Q | $-0.32 ▲ +17.1% | $-0.42 — $-0.20 | 28% YoY | 4 |
| Current FY | $-1.37 ▲ +11.1% | $-1.64 — $-1.00 | 35% YoY | 5 |
| Next FY | $-1.47 ▼ -4.6% | $-2.63 — $-0.80 | -7% YoY | 5 |
Latest Reports
BULLISH
8-K
7/10
Cabaletta Bio presented updated Phase 1/2 clinical data for rese-cel across multiple autoimmune indications at EULAR 202
Jun 5, 2026
NEUTRAL
DEFA14A
3/10
Cabaletta Bio's board withdrew Proposal 3 (amendment to the 2019 Stock Option and Incentive Plan) from the June 9, 2026
Jun 1, 2026
NEUTRAL
Press
5/10
Cabaletta Bio reported Q4 and full-year 2025 financial results, highlighted by increased R&D spending and a cash positio
Mar 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $9.7M | — |
| TWO SIGMA INVESTMENTS, LP | $4.0M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $3.3M | DOUBLED |
| MORGAN STANLEY | $2.9M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $111.3K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 2, 2026 | Chang David | A | $0.00 |
| Mar 2, 2026 | Nichtberger Steven | A | $0.00 |
| Mar 2, 2026 | Marda Anup | A | $0.00 |
| Mar 2, 2026 | Das Arun | A | $0.00 |
| Mar 2, 2026 | Gerard Michael | A | $0.00 |
Reddit Sentiment
75°
Bullish
Bearish
Neutral
Bullish
8 institutional holders with $20.2M total value (9,205,809 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, RENAISSANCE. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4,419,458 | $9.7M | 48.0% | — |
| 2 | TWO SIGMA INVESTMENTS, LP | 1,839,799 | $4.0M | 20.0% | DOUBLED +291.1% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 1,522,583 | $3.3M | 16.5% | DOUBLED +962.2% |
| 4 | MORGAN STANLEY | 1,343,708 | $2.9M | 14.6% | ADD +73.6% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 50,824 | $111.3K | 0.6% | TRIM -68.3% |
| 6 | BANK OF AMERICA CORP /DE/ | 14,392 | $31.5K | 0.2% | NEAR_EXIT -94.6% |
| 7 | FMR LLC | 13,045 | $28.6K | 0.1% | DOUBLED +271.4% |
| 8 | WELLS FARGO & COMPANY/MN | 2,000 | $4.4K | 0.0% | TRIM -33.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 470,475 | 1,839,799 | +291.1% | $4.0M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 268,058 | 14,392 | -94.6% | $31.5K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 3,000 | 2,000 | -33.3% | $4.4K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 126,100 | 1,339,423 | +962.2% | $3.1M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 252,357 | 470,475 | +86.4% | $1.1M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 498,243 | 268,058 | -46.2% | $627.3K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 6,686 | 3,000 | -55.1% | $7.0K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 984,095 | 498,243 | -49.4% | $757.3K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 10,900 | 126,100 | +1056.9% | $191.7K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 159,866 | 50,621 | -68.3% | $76.9K | 2025-Q2 |
| FMR LLC | DOUBLED | 4,161 | 15,456 | +271.4% | $23.5K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 31,979 | 6,686 | -79.1% | $10.2K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 751,894 | 321,411 | -57.3% | $445.2K | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 109,260 | 159,866 | +46.3% | $221.4K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 230,161 | 10,900 | -95.3% | $15.1K | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 40,267 | 4,161 | -89.7% | $5.8K | 2025-Q1 |
| MORGAN STANLEY | ADD | 828,829 | 1,439,165 | +73.6% | $3.3M | 2024-Q4 |
| UBS Group AG | DOUBLED | 22,774 | 434,557 | +1808.1% | $986.4K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 230,161 | — | $522.5K | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 56,911 | 204,400 | +259.2% | $464.0K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 24,162 | 40,412 | +67.3% | $91.7K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 295,509 | 828,829 | +180.5% | $3.9M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 125,845 | — | $594.0K | 2024-Q3 |
6 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | Chang David J. | Chief Medical Officer | A | 225,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Nichtberger Steven | President & CEO | A | 674,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Marda Anup | Chief Financial Officer | A | 225,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Das Arun | Chief Business Officer | A | 175,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Gerard Michael | General Counsel | A | 175,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Binder Gwendolyn | President, Science & Tech. | A | 225,000 | $0.00 | $0.00 |
11 SEC filing reports analyzed. Sentiment: 4 bullish, 3 bearish, 0 mixed, 4 neutral. Avg impact: 5.4/10.
BULLISH
8-K
7/10
Cabaletta Bio presented updated Phase 1/2 clinical data for rese-cel across multiple autoimmune indi
Jun 5, 2026
NEUTRAL
DEFA14A
3/10
Cabaletta Bio's board withdrew Proposal 3 (amendment to the 2019 Stock Option and Incentive Plan) fr
Jun 1, 2026
BULLISH
8-K
7/10
Cabaletta Bio presented new clinical data at ASGCT 2026 showing that 2 of 4 refractory pemphigus vul
May 14, 2026
BEARISH
8-K
6/10
Cabaletta Bio reported Q1 2026 net loss of $43.5M (EPS -$0.39, beating consensus of -$0.41 by ~5%) w
May 14, 2026
NEUTRAL
PRESS-RELEASE
4/10
Cabaletta Bio reported Q1 2026 EPS of -$0.40, a 3.1% miss vs consensus of -$0.39, with no revenue. T
May 14, 2026
BEARISH
8-K
7/10
Cabaletta Bio priced a $150M underwritten offering of 51.7M shares at $2.90/share, representing ~51%
May 4, 2026
BEARISH
424B5
7/10
Cabaletta Bio is selling 51,725,000 shares of common stock at $2.90 per share in a dilutive follow-o
May 4, 2026
NEUTRAL
8-K
3/10
Cabaletta Bio announced it will present new clinical and translational data from 4 refractory patien
May 4, 2026
NEUTRAL
DEFA14A
2/10
Cabaletta Bio files additional proxy materials for its 2026 annual meeting. The board recommends vot
Apr 28, 2026
BULLISH
8-K
7/10
Cabaletta Bio updated its corporate presentation with clinical data showing positive safety and effi
Apr 20, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased th
Feb 28, 2026
Current analyst consensus: Strong Buy (81% buy). Based on 16 analysts: 6 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$13.38 mean target
+315.4% upside
Strong Buy (1.50)
$4.00 Low
$30.00 High
| Metric | Value |
|---|---|
| Current Price | $3.22 |
| Target Low | $4.00 |
| Target Mean | $13.38 |
| Target Median | $13.50 |
| Target High | $30.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.34 | $-0.41 | $-0.26 | 52.7% | +21.2% | — | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-0.32 | $-0.42 | $-0.20 | 28.4% | +17.1% | — | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-1.37 | $-1.64 | $-1.00 | 34.9% | +11.1% | 1↑ 0↓ | $0.0B | 0.0% | 5 |
| Next FY 2027-12-31 |
$-1.47 | $-2.63 | $-0.80 | -7.5% | -4.6% | 1↑ 0↓ | $0.0B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.345 | |
| 7d ago | $-0.345 | |
| 30d ago | $-0.438 | +0.093 |
| 60d ago | $-0.448 | +0.103 |
| 90d ago | $-0.432 | +0.088 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| May 4, 2026 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Mar 24, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 24, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| May 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Apr 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Mar 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Feb 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Jan 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
75°
Bullish
Bearish
Neutral
Bullish
4 mentions
4 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 22, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 22, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 3, 2026
other
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
<p align="center"><em>83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all th
May 19, 2026
short_volume
Short Volume: CABA — 56.3% short (0.7M / 1.3M)
Short: 717,564 | Exempt: 6,604 | TRF Vol: 1,274,697 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: CABA — 57.3% short (0.6M / 1.1M)
Short: 622,563 | Exempt: 13,596 | TRF Vol: 1,087,053 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: CABA — 60.6% short (0.8M / 1.3M)
Short: 783,402 | Exempt: 0 | TRF Vol: 1,293,650 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV<
May 13, 2026
earnings_calendar
CABA Q1 2026 Earnings Before Market Open — 2026-05-13
May 4, 2026
other
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
<p>PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology
Apr 30, 2026
short_volume
Short Volume: CABA — 56.3% short (0.4M / 0.7M)
Short: 407,801 | Exempt: 0 | TRF Vol: 724,362 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
routine
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
<p>PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on devel
Apr 23, 2026
short_volume
Short Volume: CABA — 70.8% short (0.5M / 0.7M)
Short: 477,373 | Exempt: 400 | TRF Vol: 673,898 | Short Ratio: 70.8% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_interest
FTD: CABA — 179,500 shares ($0.6M) failed to deliver
Settlement: 20260420, Price: $3.44, FTD Value: $617,480, CABALETTA BIO INC COM
Apr 10, 2026
short_volume
Short Volume: CABA — 58.4% short (0.4M / 0.6M)
Short: 363,763 | Exempt: 1,400 | TRF Vol: 622,514 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
short_volume
Short Volume: CABA — 65.6% short (0.4M / 0.7M)
Short: 441,979 | Exempt: 108 | TRF Vol: 674,036 | Short Ratio: 65.6% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
earnings_calendar
CABA Q4 2025 Earnings After Market Close — 2026-03-30
Mar 27, 2026
short_volume
Short Volume: CABA — 60.2% short (0.9M / 1.5M)
Short: 884,999 | Exempt: 7,251 | TRF Vol: 1,470,674 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)